^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | vociprotafib (RMC-4630) (PTPN11 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects with KRASG12C Mutation After Failure of Prior Standard Therapies
Excerpt:
...Subject must have pathologically documented, locally advanced or metastatic KRASG12C NSCLC (not amenable to curative surgery) that has progressed on prior standard therapies (no more than 3 prior lines of therapies are allowed), as follows:a. ...
Trial ID:
Source:
Title:
Safety and Efficacy Study of SAR442720 in Combination With Other Agents in Advanced Malignancies
Excerpt:
...- KRAS G12C mutation....
Trial ID:
More C2 evidence
Source:
Title:
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Excerpt:
...KRAS amplifications, KRASG12C (NSCLC), BRAF Class 3, or NF1 LOF (NSCLC and gynecological cancers) mutations...
Trial ID:
Less C2 evidence
Source:
Title:
LB001 - Anti-tumor activity and tolerability of the SHP2 inhibitor RMC-4630 as a single agent in patients with RAS-addicted solid cancers
Published date:
04/09/2021
Excerpt:
...initial data from a phase 1 trial of RMC-4630 showed anti-tumor activity in tumors harboring diverse mutations in the RAS pathway including KRASG12C, KRASG12D, NF1LOF, and BRAF Class 3....Of the 80 efficacy evaluable patients, there was 1 CR (NF1LOF uterine carcinosarcoma), 1 PR (KRASG12C NSCLC), and 1 unconfirmed PR (KRASG12D NSCLC). Tumor regressions were observed in another 11 patients (-2.4% to -27.1%).
